Inverness Medical Innovations Announces Fourth Quarter 20...(GAAP Adjustments Basis(...)

Net revenue $157,008 $- $157,008

Cost of sales 89,680 (3,906)(b)(c)(d) 85,774

Gross profit 67,328 3,906 71,234

Gross margin 43% 45%

Operating expenses:

Research and

development 13,917 (1,460)(c)(d) 12,457

Purchase of in-process

research and

development - - -

Selling, general and

administrative 44,584 (2,493)(c)(d) 42,091

Loss on dispositions,

net 307 (307)(e) -

Operating income 8,520 8,166 16,686

Interest and other income

(expense), net (650) 177(c) (473)

Income tax (benefit)

provision 1,843 552(i) 2,395

Net (loss) income $6,027 $7,791 $13,818

Net (loss) income per

common share:

Basic $0.15 $0.36

Diluted $0.15(l) $0.34(l)

Weighted average common

shares - basic 38,885 38,885

Weighted average common

shares - diluted 40,715(l) 40,715(l)

(a) In calculating net income or loss on an adjusted cash basis, the

Company excludes from net income or loss (i) certain non-cash

charges including amortization expense and stock-based compensation

expense, (ii) non-recurring charges and income, and (iii) certain

other charges and income that have a sign
'/>"/>